Volume 6, Issue 3

GOG FOUNDATION®
Transforming the standard of care™

November 2026

GOG PARTNERS CONNECTION

A Quarterly Newsletter From GOG Partners, A GOG Foundation Program

THE PRESIDENT'S REPORT

Cure and Curative Potential in Endometrial and Ovarian Cancer



Thomas Herzog, MD
President, The GOG Foundation, Inc.
University of Cincinnati

One of the most meaningful questions our patients ask is, "Am I cured?" As advances in immunotherapy, targeted therapies, and maintenance treatments continue to improve outcomes for patients with gynecologic cancers, that question is becoming increasingly relevant.

Recent clinical trials with novel agents have demonstrated prolonged remission and long-term disease control for many patients with endometrial and ovarian cancers, prompting important discussions about curative potential and how we communicate hope, prognosis, and uncertainty in this new era.

Five-year follow-up from SOLO1 showed median progression-free survival of 56 months with olaparib maintenance in BRCA-mutated ovarian cancer, versus 13.8 months with placebo. In mismatch repair deficient endometrial cancer, four-year RUBY data showed PFS was 57.9% with dostarlimab plus chemotherapy, compared to 15.7% with chemotherapy alone. For a growing number of our patients, "Am I cured?" is no longer a hypothetical question, it is one that they are asking us directly.

To address this evolving landscape, The GOG Foundation, Inc. (GOG-F) launched the CURE initiative, bringing together clinicians, researchers, patient advocates, caregivers, and survivors to develop evidence-based recommendations for discussing cure and curative potential in gynecologic oncology. Through multidisciplinary roundtables, surveys, and a comprehensive review of available data, the initiative has resulted in a consensus manuscript, *Cure and Curative Potential in Endometrial and Ovarian Cancer: A GOG Foundation Consensus Paper*.

The intent of this publication is not to redefine cure, but rather to provide clinicians with a thoughtful framework for discussing favorable outcomes while maintaining transparency about what remains unknown. The manuscript emphasizes the importance of balancing optimism with evidence, ensuring that patients receive reassurance that is both meaningful and medically appropriate.

As we prepare this work for publication, we are proud of the collaborative effort behind it and grateful to the many patients, advocates, and experts who contributed their perspectives. We believe this manuscript represents an important step toward improving communication, supporting survivorship, and helping patients navigate life beyond a cancer diagnosis with greater confidence and understanding.

I want to thank our roundtable participants, and especially the patients and caregivers who were willing to describe, in their own words, what reassurance has and has not meant to them. Their voices shaped this paper as much as the contemporary trial data, if not more.

I look forward to sharing the insights and recommendations from this important work with the broader gynecologic oncology community and encourage readers to keep an eye out for the manuscript's publication in 2027.

Volume 6, Issue 3

GOG-F/SGO Bridges 3.0 Research Initiative

The GOG Foundation, Inc. (GOG-F) and the Society of Gynecologic Oncology (SGO) Bridges 3.0 Research Initiative is a two-year, longitudinal clinical trials program designed for early-career investigators in gynecologic oncology. Its mission is to develop the next generation of trialists who will lead investigator-initiated and cooperative group gynecologic cancer clinical studies that advance the care of patients with gynecologic cancers.

SGO / GOG-F BRIDGES RESEARCH INITIATIVE

SGO | GOG FOUNDATION

By "bridging" the gap between translational science and clinical investigation, the program provides participants with formal training in clinical trial design and implementation, access to expert mentorship, and hands-on experience developing innovative research concepts. Through a combination of education, mentorship, and experiential learning, Bridges 3.0 equips emerging investigators with the skills, knowledge, and professional network necessary to become future leaders in gynecologic oncology research.

Click here to learn more about this program and to submit your application.

Application Deadline Extension: November 9, 2026 at 11:59 pm CT


Society of Pelvic Surgeons and GOG-F Partnership

Society of Pelvic Surgeons (SPS) Selects The GOG Foundation, Inc. (GOG-F) as Management Partner to Advance Multidisciplinary Surgical Collaboration Worldwide

The GOG Foundation, Inc., a nonprofit organization dedicated to advancing clinical research and improving outcomes for patients with gynecologic cancers, today announced that it has assumed management responsibilities for the Society of Pelvic Surgeons (SPS), a distinguished global organization that brings together experts in gynecology, urology, and colorectal surgery to advance the science and practice of pelvic surgery.

Founded on the principle that collaboration across specialties improves patient care, the SPS has served as a unique forum for surgeons from around the world to share innovations, research findings, and clinical expertise. Through its annual scientific meetings, such as the meeting that took place October 7-10, 2026, in Banff, Alberta, Canada, and active international membership, SPS fosters multidisciplinary education and promotes the exchange of ideas that lead to advances in diagnosis, treatment, and surgical techniques.

Click here to read the full press release.



Volume 6, Issue 3

GOG FOUNDATION®
Transforming the standard of care™

NEW HORIZONS
Support Our Mission

Fellows Forum 2027 Annual Meeting

The GOG Foundation, Inc. (GOG-F) is pleased to announce the National Gynecologic Oncology Fellows Forum. This dynamic program is designed to foster the next generation of leaders in gynecologic oncology.

This important initiative aims to equip emerging researchers with the essential skills in leadership, effective presentation, and meaningful engagement, providing them with the tools needed to excel in their careers and drive forward advancement in clinical research in the field of gynecologic oncology.

Through a series of focused sessions, interactive opportunities, and mentorship engagement, the National Gynecologic Oncology Fellows Forum will support young investigators in refining their expertise and making impactful contributions in gynecologic oncology.

Click here to learn more about the National Gynecologic Oncology Fellows Forum.

2027 Faculty



MARIO LEITAO, MD
Memorial Sloan Kettering Cancer Center
New York, New York, USA



FLOOR BACKES, MD
The Ohio State University
Comprehensive Cancer Center
Columbus, Ohio, USA



RAMEZ ESKANDER, MD
UC San Diego Moores
Comprehensive Cancer Center
San Diego, California, USA



HEIDI GRAY, MD
UW Medicine
Seattle, Washington, USA



KENNETH KIM, MD
ABOG
Dallas, Texas, USA



THOMAS KRIVAK, MD
Allegheny Health Network
Pittsburgh, Pennsylvania, USA



MARTY MARTINO, MD
Ascension St. Vincent's
Jacksonville, Florida, USA



SUSAN MODESITT, MD
Emory University
School of Medicine
Atlanta, Georgia, USA



BRIAN SLOMOVITZ, MD
Mount Sinai Medical Center
Miami Beach, Florida, USA



PAMELA SOLIMAN, MD
MD Anderson Cancer Center
Houston, Texas, USA



J. MICHAEL STRAUGHN, MD
UAB Medicine
Birmingham, Alabama, USA



TODD TILLMANNS, MD
West Cancer Center
Research Institute
Memphis, Tennessee, USA



CHRISTINE WALSH, MD
University of Colorado Hospital,
Anschutz Cancer Pavilion
Aurora, Colorado, USA



April 28 - May 1, 2027

The Joseph Hotel
Nashville, Tennessee

Call for Abstracts Opening Monday, November 9, 2026

Deadline to submit is Wednesday, January 6, 2027

Click Here For More Information

CLINICAL TRIALS

The GOG Partners (GOG-P) Program is currently recruiting for 33 clinical trials:

- **20 Ovary**
- **3 Cervix**
- **10 Endometrium**

Search Active Clinical Trials

To learn more about GOG-P Clinical Trials, please contact Katie Campbell-Simms, BS at kcampbell@gog.org.



Katie Campbell-Simms, BS
Executive Director, Clinical Trials Operations
The GOG Foundation, Inc.

BEHOLD Trials Recruitment Announcement

The international collaboration between The GOG Foundation, Inc. (GOG-F) and ENGOT continues to progress, with three more Phase 3 clinical trials reaching or approaching first-patient milestones.

The first patient has now been dosed in two studies, with dosing anticipated in the other. All three are randomized, multicenter, open-label Phase 3 ENGOT Model C trials investigating mocertatug rezetecan (Mo-Rez) in different ovarian and endometrial cancer settings:

GOG-3136/ENGOT-ov99/MaNGO/BEHOLD-Ovarian02
This trial compares Mo-Rez in combination with bevacizumab versus platinum-doublet chemotherapy plus bevacizumab in patients with platinum-sensitive ovarian cancer. The first patient has been dosed in the Republic of Korea. The trial is led internationally by GOG-F with lead principal investigator Ramez Eskander, MD, with MaNGO - Mario Negri Gynecologic Oncology leading the cooperating ENGOT groups, and Annamaria Ferrero, MD, PhD as ENGOT principal investigator.

Click here for more information on this trial.

GOG-3130/ENGOT-en33/GINECO-EN205/BEHOLD-Endometrial02
This trial evaluates Mo-Rez in combination with immunotherapy as maintenance treatment, compared with immunotherapy alone, in patients with mismatch repair-proficient advanced or recurrent endometrial cancer. The first patient has been dosed in Japan. The trial is led internationally by Isabelle Ray-Coquard, MD, PhD, and by GOG-F with lead principal investigator Bradley Corr, MD.

Click here for more information on this trial.

GOG-3135/ENGOT-ov105/MITO/BEHOLD-Ovarian03
This trial evaluates Mo-Rez with or without bevacizumab as maintenance treatment, compared with active observation with or without bevacizumab, in patients with newly diagnosed advanced ovarian cancer without homologous recombination deficiency. First-patient dosing is anticipated in November in Argentina. The trial is led internationally by MITO with Sandro Pignata, MD as principal investigator, and by GOG-F lead principal investigator Rachel Grisham, MD.

Click here for more information on this trial.

We would like to thank the patients participating in these studies, as well as the investigators, cooperating groups and clinical research teams working together to advance this research.

PUBLICATIONS

GOG-3057/ENGOT-cx12/innovaTV 301 IJGC Publication

On November 2, 2026: Patient-reported outcomes with tisotumab vedotin versus chemotherapy in patients with recurrent or metastatic cervical cancer: post hoc analyses from the open-label, randomized, phase 3 ENGOT-cx12/GOG-3057/ innovaTV 301 trial

Click here to read the full publication.

GOG-3095/ENGOT-en23/TroFuse-005 Lancet Publication

On October 26, 2026: Sacituzumab tirumotecan versus treatment of physician's choice in previously treated endometrial cancer (TroFuse-005/ENGOT-en23/GOG-3095): a randomized, open-label, phase 3 trial

Click here to read the full publication.

GOG-3064/ENGOT-en15/KEYNOTE-C93 Lancet Publication

On October 26, 2026: First-line pembrolizumab versus carboplatin plus paclitaxel in participants with mismatch repair-deficient advanced or recurrent endometrial cancer (KEYNOTE-C93/GOG-3064/ENGOT-en15): interim analysis of a multicenter, open-label, randomized, active-comparator controlled, phase 3 trial

Click here to read the full publication.

GOG-3031/ENGOT-en6-NSGO/RUBY Part 2 Trial IJGC Publication

On July 25, 2026: Poly(adenosine diphosphate-ribose) polymerase inhibitor maintenance therapy with niraparib in patients with primary advanced or recurrent endometrial cancer receiving dostarlimab plus chemotherapy

Click here to read the full publication.

GSK


Learn More About Endometrial and Ovarian Cancer

Visit GSK's Gynecologic Oncology YouTube Channel

Click here to visit the channel

For US Healthcare Professionals only

PSE-US-4980 | Mar 2026



IN THE NEWS

GOG-3107/ENGOT-ov86/ RAINFOL-02 Press Release

On October 23, 2026: Genmab Announces Rinatabart Sesutecan (Rina-S®) Demonstrates Statistically Significant Improvement in Progression-Free Survival and Overall Survival in Patients with Platinum-Resistant Ovarian Cancer

Click here to read full press release.

GOG-3066/DENALI Press Release

On October 23, 2026: Zentalis Pharmaceuticals Announces Meaningful Median Overall Survival Data in Cyclin E1-Positive Platinum-Resistant Ovarian Cancer from DENALI Part 1b to be Presented at the ESMO Congress 2026

Click here to read full press release.

GOG-3132/BEHOLD-Ovarian01 Press Release

On July 27, 2026: First patient enrolled in GOG-3132/BEHOLD-Ovarian01 phase 3 study evaluating Mocertatug Rezetecan, a novel B7-H4–targeted ADC, in platinum-resistant ovarian cancer

Click here to read full press release.



GOG FOUNDATION®

GYN-LIVE PODCAST

Transforming the standard of care in gynecologic oncology so our patients can answer the why questions for their next generation.


RECENT PODCAST EPISODES

[Click here](#) to listen to these audio podcasts on your favorite streaming channel.

[Click here](#) to watch these video podcasts on YouTube.









LET'S CONNECT

@gogfoundation.bsky.social


@GOGFOUNDATION

@gog_foundation

The GOG Foundation, Inc.

@gogfoundation3870

@GOG



ENDURING EDUCATION


IGCS 2026 Industry Supported Symposia (ISS)

The 2026 IGCS ISS session recordings are now available on the IGCS Education360 Learning Portal. Note you must be registered for the IGCS 2026 Congress to access the recordings. The recordings will be available on IGCS Education360 until January 4, 2027.

- Once you are logged into the Education360 Learning Portal, select “My Courses” on the left panel.
- From the list of your courses, find “IGCS 2026 Annual Global Meeting - On-Demand”.
- Within this course, you will find recordings, abstracts, ePosters, and surgical films.

The 2026 IGCS ISS session recordings will be available to the public on the GOG-F website from January 4, 2027 – July 5, 2027.

FSGO 2026 Industry Supported Symposia (ISS)



Evolving Evidence and Treatment Strategies in Platinum Resistant Ovarian Cancer: From Biology to Bedside

Click here to access the enduring educational materials

This educational activity is supported by an independent medical education grant from Corcept Therapeutics.



Future of ADCs: Accelerating Progress in Ovarian and Endometrial Cancer

Click here to access the enduring educational materials

This educational activity is supported by an independent medical education grant from GSK.



ctDNA-based MRD Testing and Monitoring in Gynecologic Cancers

Click here to access the enduring educational materials

This educational activity is supported by an independent medical education grant from Natera.




Evolving Evidence and Treatment Strategies in Low Grade Serous Ovarian Cancer

Click here to access the enduring educational materials

This educational activity is supported by an independent medical education grant from Verastem Oncology.

UPCOMING INDUSTRY MEETINGS

SGO 2027 Winter Meeting



January 21–23, 2027 | Lake Louise, Alberta, Canada

The SGO Winter Meeting fosters collaboration among researchers at all career stages through specialized scientific sessions, insightful posters, and intimate networking events.

Click here for more information on the meeting.

NRG Semiannual 2027 Winter Meeting



January 28–30, 2027 | Caesars Palace | Las Vegas, Nevada

Join us in Las Vegas for the NRG Winter 2027 Semiannual Meeting. This year's program will feature:

- Scientific sessions highlighting the latest in clinical research
- Educational sessions for early-career investigators
- Networking opportunities with colleagues across oncology disciplines
- An expanded Winter Symposium

Click here for more information on the meeting.

The GOG Highlight Reel - January 2027

Friday, January 29, 2027 | 7:00 pm – 9:30 pm | Las Vegas, Nevada
In conjunction with the NRG Semiannual 2027 Winter Meeting

The GOG Highlight Reel is a 2.5-hour course that distills practice-changing data from recent major medical meetings into key takeaways for gynecologic oncology. Covering ovarian, endometrial, and cervical cancers, it reviews new trial results, approved therapies, and investigational agents, giving physicians a clear, up-to-date view of the evolving treatment landscape.

Registration will open in late November 2026.

ESGO 2027 Congress

February 25–27, 2027 | London, United Kingdom

The 28th Congress of the European Society of Gynaecological Oncology will bring together over 4,000 attendees from around the world for a gathering of learning, networking, and sharing the latest developments in the field of gynaecological cancers – all with the goal of enhancing your knowledge, accelerating your skills and advancing the field.

Click here for more information on the meeting.

GOG 2026 INDUSTRY SPONSORS

The GOG-F and GOG-P would like to thank our Year-Round Sponsors for their support of our mission to transform the standard of care in gynecologic oncology.

PREMIER SPONSORS

Corcept THERAPEUTICS

GSK

Pfizer

PARTNER SPONSORS

Genmab

Lilly

MERCK

natera

VERASTEM ONCOLOGY

SUPPORTING SPONSORS

BeOne

BIONTECH

Bristol Myers Squibb™

FOUNDATION MEDICINE®

Genentech
A Member of the Roche Group

PMVPharma

REGENERON®

zentalis
more choice. more possibility.™

The GOG is grateful for our Industry Collaboration Team Members

PLATINUM MEMBERS

abbvie

AstraZeneca

Daiichi-Sankyo

GOLD MEMBERS

Eisai, Inc.

Gilead | Kite